International Journal of Hematology

, Volume 73, Issue 3, pp 351–355 | Cite as

Successful Combination Therapy—Flunarizine, Pentoxifylline, and Cholestyramine— for Spur Cell Anemia

  • Ken-ichi Aihara
  • Hiroyuki Azuma
  • Yasumasa Ikeda
  • Masashi Akaike
  • Masahiro Abe
  • Takashi Sugihara
  • Toshio Matsumoto
Case Report


Spur cell anemia, a hemolytic anemia observed in patients with alcoholic cirrhosis, is characterized by unusual erythrocyte morphology and an increased ratio of free cholesterol to phospholipid in the erythrocyte membrane.The prognosis of spur cell anemia is usually extremely poor, however, we describe here a patient with spur cell anemia who was successfully treated with combination therapy consisting of flunarizine, pentoxifylline, and cholestyramine. Initial therapy with flunarizine alone for 6 weeks did not significantly decrease the number of spur cells on peripheral blood smears. So pentoxifylline was added to the regimen.The patient recovered from the anemia, showed remarkable improvement with regard to the hyperbilirubinemia, and the changes were accompanied by a significant decrease in the number of spur cells in peripheral blood smears. To correct the hypercholesterolemia, cholestyramine was added to the regimen, which resulted in a reduction in the serum level of free cholesterol and an increase in the molar ratio of free cholesterol to phospholipid in erythrocyte membrane. However, 6 months later a skin eruption developed that was considered an adverse reaction to the drugs, so the flunarizine and pentoxifylline were discontinued. With cholestyramine therapy alone, the remission of spur cell anemia was maintained for more than 11 months. These observations suggest that non-invasive combination therapy with flunarizine, pentoxifylline, and cholestyramine is effective and valuable in the treatment of patients with spur cell anemia.

Key words

Spur cell anemia Free cholesterol Hepatosplenomegaly Pentoxifylline Cholestyramine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Smith JA, Lonergan ET, Sterling K. Spur cell anemia. Hemolytic anemia with red cell resembling acanthocyte in alcoholic cirrhosis.N Engl J Med. 1964;271:396–398.CrossRefPubMedGoogle Scholar
  2. 2.
    Cooper RA, Puray MD, Land P, Greenberg MS. An analysis of lipoproteins, bile acids, and red cell membranes associated with target cells and spur cells in patients with liver disease.J Clin Invest. 1972;51:3182–3192.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Allen DW, Manning N. Cholesterol-loading of membranes of normal erythrocytes inhibits phospholipid repair and arachidonoyl- CoA:1-palmitoyl-sn-glycero-3-phosphocholine acyl transferase: a model of spur cell anemia.Blood. 1996;87:3489–3493.PubMedGoogle Scholar
  4. 4.
    Fukuda T, Baba Y, Tanaka M, et al. Severe alcoholic cirrhosis associated with spur cell anemia and DIC.Fukuoka Igaku Zasshi. 1991;82:398–402.PubMedGoogle Scholar
  5. 5.
    Doll DC, Doll NJ. Spur cell anemia.South Med J. 1982;75:1205–1210.CrossRefPubMedGoogle Scholar
  6. 6.
    Thomson A, Kerlin P, Clouston A, Cobcroft R. Spur cell anaemia resolves after orthotopic liver transplantation (OLT).Aust N Z J Med. 1997;27:198–199.CrossRefPubMedGoogle Scholar
  7. 7.
    Chitale AA, Sterling RK, Post AB, Silver BJ, Mulligan DC, Schulak JA. Resolution of spur cell anemia with liver transplantation. A case report and review of the literature.Transplantation. 1998;65:993–995.CrossRefPubMedGoogle Scholar
  8. 8.
    Fossaluzza V, Rossi P. Flunarizine treatment for spur cell anemia.Br J Hematol. 1983;55:715–717.CrossRefGoogle Scholar
  9. 9.
    Nishio T, Toshima Y, Matsuno Y. Effects of pentoxifylline on cell shape, ATP content and deformability in rabbit erythrocytes under hyperosmolar conditions.Int J Biochem. 1982;14:915–920CrossRefPubMedGoogle Scholar
  10. 10.
    Conrad ME, Barton JC. Anemia and iron kinetics in alcoholism.Semin Hematol. 1980;17:149–163.PubMedGoogle Scholar
  11. 11.
    Zieve L. Jaundice, hyperlipemia and hemolytic anemia: a heretofore unrecognized syndrome associated with alcoholic fatty liver and cirrhosis.Ann Intern Med. 1958;48:471–496CrossRefPubMedGoogle Scholar
  12. 12.
    Clemens MR, Einsele H, Remmer H. Alcohol consumption and hepatic fibrosis affect the fatty acid composition of red blood cells and their susceptibility to lipid peroxidation.Arch Toxicol. 1987;60:167–169.CrossRefPubMedGoogle Scholar
  13. 13.
    Cooper RA, Kimball DB, Durocher JR. Role of the spleen in membrane conditioning and hemolysis of spur cells in liver disease.N Engl J Med. 1974;290:1279–1284.CrossRefPubMedGoogle Scholar
  14. 14.
    Balistreri WF, Leslie MH, Cooper RA. Increased cholesterol and decreased fluidity of red cell membranes (spur cell anemia) in progresive intrahepatic cholestasis.Pediatrics. 1981;67:461–466.PubMedGoogle Scholar
  15. 15.
    Takakura Y, Mohandas N. Modulation of erythrocyte membrane material properties by Ca2+ and calmodulin. Implications for their role in regulation of skeletal protein interactions.J Clin Invest. 1988;82:394–400.CrossRefGoogle Scholar
  16. 16.
    Scott CK, Persico FJ, Carpenter K, Chasin M. The effects on flunarizine, a new calcium antagonist, on human red blood cells in vitro.Angiology. 1980;31:320–330.CrossRefGoogle Scholar
  17. 17.
    Morse EE. Mechanisms of hemolysis in liver disease.Ann Clin Lab Sci. 1990;20:169–174.PubMedGoogle Scholar
  18. 18.
    Yasuhara H,Tonooka M, Kamei K, Sakamoto K. Membrane effect of various drugs on isolated hepatocytes and erythrocytes.Toxicol Appl Pharmacol. 1985;79:453–460.CrossRefPubMedGoogle Scholar
  19. 19.
    Angelin B, Bjorkhem I, Einarsson K, Ewerth S. Cholestyramine treatment reduces postprandial but not fasting serum bile acid levels in humans.Gastroenterology. 1982;83:1097–1101.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2001

Authors and Affiliations

  • Ken-ichi Aihara
    • 1
  • Hiroyuki Azuma
    • 1
  • Yasumasa Ikeda
    • 1
  • Masashi Akaike
    • 1
  • Masahiro Abe
    • 1
  • Takashi Sugihara
    • 2
  • Toshio Matsumoto
    • 1
  1. 1.First Department of Internal MedicineUniversity of Tokushima School of MedicineTokushima
  2. 2.Division of Hematology, Department of MedicineKawasaki Medical SchoolOkayamaJapan

Personalised recommendations